Identification

Name
Iron Dextran
Accession Number
DB00893  (APRD01053)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

Synonyms
  • Dextran iron
  • Iron dextran complex
External IDs
UNII-95HR524N2M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DexferrumInjection, solution50 mg/mLIntravenousAmerican Regent1996-03-01Not applicableUs
DexferrumInjection, solution50 mg/mLIntravenousAmerican Regent1998-10-01Not applicableUs
INFeDInjection50 mg/mLIntramuscular; IntravenousActavis Pharma Company1974-04-29Not applicableUs
InfedInjection, solution50 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-01Not applicableUs
International/Other Brands
CosmoFer (B. Braun) / Dexferrum / Feosol (GlaxoSmithKline) / Imferon (Sanofi-Aventis) / Proferdex (New River Pharmaceuticals Inc.)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralMeda Pharmaceuticals Ltd2012-10-31Not applicableUs
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralAlaven Pharmaceutical2010-05-01Not applicableUs68220 0085 90 nlmimage10 2d1316d8
Iron Polysaccharides Folic Acid DHAIron Dextran (29 mg/1) + Beta carotene (1100 [iU]/1) + Cholecalciferol (1000 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (200 mg/1) + Folic Acid (1 mg/1) + Magnesium oxide (20 mg/1) + Nicotinamide (15 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Vitamin C (30 mg/1) + Vitamin E (20 mg/1) + Zinc oxide (25 mg/1)Tablet, film coatedOralVirtus Pharmaceuticals2013-12-202017-08-11Us
NiferexIron Dextran (100 mg/1) + Cyanocobalamin (25 ug/1) + Ferrous asparto glycinate (50 mg/1) + Folic Acid (250 ug/1) + Gastric intrinsic factor (100 mg/1) + Levomefolic acid (750 ug/1) + Succinic acid (50 mg/1) + Vitamin C (60 mg/1) + Zinc (15 mg/1)TabletOralAvion Pharmaceuticals, Llc2017-01-23Not applicableUs
Prefera OB plus DHAIron Dextran (22 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate (.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Vitamin E succinate (10 [iU]/1) + Zinc oxide (15 mg/1)TabletOralAlaven Pharmaceutical2009-04-01Not applicableUs
PreferaOBIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate (.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Vitamin E succinate (10 [iU]/1) + Zinc oxide (4.5 ug/1)TabletOralAlaven Pharmaceutical2010-09-27Not applicableUs
PreferaOB OneIron Dextran (22 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (12 ug/1) + Doconexent (200 mg/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Vitamin C (25 mg/1) + Vitamin E (10 [iU]/1) + Zinc oxide (15 ug/1)CapsuleOralAlaven Pharmaceutical2010-04-01Not applicableUs
PreferaOB plus DHAIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate (.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic Acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Vitamin E succinate (10 [iU]/1) + Zinc oxide (4.5 ug/1)TabletOralAlaven Pharmaceutical2010-11-15Not applicableUs
PureVit DualFe PlusIron Dextran (53 mg/1) + Cupric sulfate (.8 mg/1) + Cyanocobalamin (15 ug/1) + Folic Acid (1 mg/1) + Ferrous fumarate (53 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Thiamine mononitrate (10 mg/1) + Sodium ascorbate (200 mg/1) + Zinc sulfate (18.2 mg/1)CapsuleOralPure Tek Corporation2011-06-01Not applicableUs
Se-Tan DHAIron Dextran (15 mg/1) + Doconexent (215.12 mg/1) + Folic Acid (1 mg/1) + Icosapent (53.46 mg/1) + Ferrous fumarate (15 mg/1) + Omega-3 fatty acids (310.1 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Sodium ascorbate (20 mg/1)Capsule, gelatin coatedOralSeton Pharmaceuticals2009-10-012016-04-30Us
Categories
UNII
95HR524N2M
CAS number
9004-66-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.

Structured Indications
Pharmacodynamics

Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.

Mechanism of action

After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

TargetActionsOrganism
AHemoglobin subunit beta
activator
Human
AHemoglobin subunit alpha
activator
Human
AFerritin heavy chain
other
Human
AFerritin light chain
other
Human
Absorption

The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.

Volume of distribution
Not Available
Protein binding

100% (after release from dextran)

Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of elimination

Dextran, a polyglucose, is either metabolized or excreted.

Half life

5 hours (some indications that it can be as long as 10 hours)

Clearance
Not Available
Toxicity

LD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlgeldrateAlgeldrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmagateAlmagate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron Dextran.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.Approved
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Iron Dextran.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.Approved
CimetidineCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational, Withdrawn
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Iron Dextran.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Iron Dextran.Experimental
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexlansoprazoleDexlansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexrabeprazoleDexrabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DimercaprolDimercaprol may increase the nephrotoxic activities of Iron Dextran.Approved
Dipotassium phosphateIron Dextran can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Iron Dextran.Approved
DoxepinDoxepin can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Iron Dextran.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
EpinastineEpinastine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Iron Dextran.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Iron Dextran.Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Iron Dextran.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Iron Dextran.Investigational, Withdrawn
HydrotalciteHydrotalcite can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Iron Dextran.Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Iron Dextran.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Iron Dextran.Approved
Lipoic AcidIron Dextran can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Iron Dextran.Approved
MetiamideMetiamide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Iron Dextran.Approved, Investigational
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Iron Dextran.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Iron Dextran.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Iron Dextran.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Iron Dextran.Experimental
PancrelipasePancrelipase can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PantoprazolePantoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Iron Dextran.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Iron Dextran.Approved
PenicillamineIron Dextran can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron Dextran.Approved
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Iron Dextran.Experimental
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Iron Dextran.Experimental
PromethazinePromethazine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron Dextran.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.Approved, Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Iron Dextran.Approved
RanitidineRanitidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Iron Dextran.Experimental
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Iron Dextran.Experimental, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateIron Dextran can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateIron Dextran can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Iron Dextran.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Iron Dextran.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron Dextran.Experimental, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Iron Dextran.Approved
TriethylenetetramineThe serum concentration of Iron Dextran can be decreased when it is combined with Triethylenetetramine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Iron Dextran.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Iron Dextran.Experimental
Food Interactions
Not Available

References

Synthesis Reference

William T. Monte, Laurie Scaggs, "Process for making crystalline iron dextran." U.S. Patent US5756715, issued 1905.

US5756715
General References
Not Available
External Links
KEGG Drug
D02141
PubChem Substance
46506136
ChEMBL
CHEMBL1201544
Therapeutic Targets Database
DAP001312
PharmGKB
PA164764618
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
MSDS
Download (45.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentPostpartum Anemia1
2CompletedTreatmentAnemias / Non-Myeloid Malignancies1
2CompletedTreatmentPregnancy1
2Unknown StatusTreatmentIron Deficiency Anemia (IDA)2
3CompletedTreatmentAnemias1
4CompletedTreatmentTreatment of Iron Deficiency Anemia in Pregnancy1
4SuspendedTreatmentIron Deficiency Anemia (IDA) / Perioperative Blood Conservation1
4TerminatedTreatmentAnemias1
4Unknown StatusTreatmentPreterm Anemia1
Not AvailableEnrolling by InvitationBasic ScienceIron Deficiency1

Pharmacoeconomics

Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous50 mg/mL
InjectionIntramuscular; Intravenous50 mg/mL
Injection, solutionIntramuscular; Intravenous50 mg/mL
Tablet, film coatedOral
TabletOral
CapsuleOral
Capsule, gelatin coatedOral
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USD ml
Dexferrum 100 mg/2 ml vial21.6USD ml
Dexferrum 50 mg/ml vial21.6USD ml
Dexiron 50 mg/ml15.66USD ml
Infufer 50 mg/ml15.53USD ml
Infed 100 mg/2 ml vial14.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5624668No1995-09-292015-09-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an...
Gene Name
HBB
Uniprot ID
P68871
Uniprot Name
Hemoglobin subunit beta
Molecular Weight
15998.34 Da
References
  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. [PubMed:9629498]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
Gene Name
FTH1
Uniprot ID
P02794
Uniprot Name
Ferritin heavy chain
Molecular Weight
21225.47 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a ro...
Gene Name
FTL
Uniprot ID
P02792
Uniprot Name
Ferritin light chain
Molecular Weight
20019.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. [PubMed:10084288]
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. [PubMed:11576368]
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. [PubMed:17316146]
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. [PubMed:2208657]
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. [PubMed:272031]

Drug created on June 13, 2005 07:24 / Updated on November 06, 2017 06:43